share_log

424B3: Prospectus

424B3: Prospectus

424B3：募资说明书
美股SEC公告 ·  04/23 16:06
Moomoo AI 已提取核心信息
Adial Pharmaceuticals, Inc. has filed a prospectus related to the resale of up to 2,369,000 shares of common stock by Selling Stockholders. The shares are associated with Series C Common Warrants and Placement Agent Warrants issued in a private placement transaction that closed on March 6, 2024. The Selling Stockholders include certain identified stockholders and designees of H.C. Wainwright & Co., LLC, the placement agent for the private placement. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their stock, as the sale is at their discretion. Adial Pharmaceuticals will not offer any shares under this prospectus and will not receive proceeds from the sale of the shares by the Selling Stockholders. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of April 10, 2024, the closing price of Adial's common stock was $2.33 per share. The date of the prospectus is April 19, 2024.
Adial Pharmaceuticals, Inc. has filed a prospectus related to the resale of up to 2,369,000 shares of common stock by Selling Stockholders. The shares are associated with Series C Common Warrants and Placement Agent Warrants issued in a private placement transaction that closed on March 6, 2024. The Selling Stockholders include certain identified stockholders and designees of H.C. Wainwright & Co., LLC, the placement agent for the private placement. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their stock, as the sale is at their discretion. Adial Pharmaceuticals will not offer any shares under this prospectus and will not receive proceeds from the sale of the shares by the Selling Stockholders. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of April 10, 2024, the closing price of Adial's common stock was $2.33 per share. The date of the prospectus is April 19, 2024.
Adial Pharmicals, Inc.已提交了一份招股说明书，内容涉及卖出股东转售多达2369,000股普通股。这些股票与在2024年3月6日结束的私募交易中发行的C系列普通认股权证和配售代理认股权证有关。出售股东包括私募配售代理机构H.C. Wainwright & Co., LLC的某些特定股东和指定人。这些股票的注册并不一定意味着卖出股东将出售其股票，因为出售由他们自行决定。Adial Pharmicals不会根据本招股说明书发行任何股票，也不会获得出售股东出售股票的收益。但是，该公司将从认股权证的任何现金行使中获得收益。普通股在纳斯达克资本市场上市，股票代码为 “ADIL”。截至2024年4月10日，阿迪亚尔普通股的收盘价为每股2.33美元。招股说明书的发布日期为2024年4月19日。
Adial Pharmicals, Inc.已提交了一份招股说明书，内容涉及卖出股东转售多达2369,000股普通股。这些股票与在2024年3月6日结束的私募交易中发行的C系列普通认股权证和配售代理认股权证有关。出售股东包括私募配售代理机构H.C. Wainwright & Co., LLC的某些特定股东和指定人。这些股票的注册并不一定意味着卖出股东将出售其股票，因为出售由他们自行决定。Adial Pharmicals不会根据本招股说明书发行任何股票，也不会获得出售股东出售股票的收益。但是，该公司将从认股权证的任何现金行使中获得收益。普通股在纳斯达克资本市场上市，股票代码为 “ADIL”。截至2024年4月10日，阿迪亚尔普通股的收盘价为每股2.33美元。招股说明书的发布日期为2024年4月19日。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息